20 completed, 3 unknown, 2 withdrawn, 1 active not recruiting. 27 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 20, Unknown 3, Withdrawn 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 7 | Completed 6, Unknown 1 |
Follow Opioid Dependence: new trials by email Literature Review of Opioid Dependence trials Research Report on Opioid Dependence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction 250mg healthy adult male facial skin surface lipid liquid pheromone - Opioid Addiction, Opioid Abuse, Continuous Use | Phase 3 | Unknown | Bubba Nicholson | 500 | 2020-12-31 | 2020-10-19 |
| An Innovative Intervention for OUD Treatment Bridge Device, Lofexidine, Placebo - Opioid-Related Disorders, Opioid Dependence | Phase 2 / Phase 3 | Completed | Johns Hopkins University | 36 | 2020-11-15 | 2026-06-09 |
| Community Studies of Long Acting Buprenorphine (CoLAB) RBP-6000 - Opioid Dependence | Phase 3 | Unknown | The University of New South Wales | 100 | 2019-05-22 | 2020-03-05 |
| Facilitating Rapid Naltrexone Initiation CI-581-a, CI-581-b - Opioid Dependence | Phase 3 | Active not recruiting | New York State Psychiatric Institute | 100 | 2017-11-25 | 2024-02-02 |
| Comparing Opium Tincture (OT) With Methadone for Medication-assisted Treatment of Opioid Use Disorder opium, methadone - Opioid Dependence | Phase 3 | Completed | University of British Columbia | 204 | 2017-06-22 | 2019-07-12 |
| Liposomal Bupivacaine for Pain Control Following Thoracic Surgery. Liposomal bupivacaine, Bupivacaine, Epinephrine - Pain, Postoperative, Thoracic Diseases | Phase 2 / Phase 3 | Unknown | Massachusetts General Hospital | 200 | 2017-02-01 | 2017-01-30 |
| Buprenorphine Treatment for Opioid Dependence Buprenorphine - Opioid Dependence | Phase 3 | Completed | Yale University | 9 | 2015-03-01 | 2023-03-10 |
| Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine SUBOXONE, RBP-6000, Placebo - Opioid Dependence, Opioid Related Disorders | Phase 3 | Completed | Indivior Inc. | 665 | 2015-01-28 | 2018-02-20 |
| Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone Buprenorphine/naloxone - Opioid Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 30 | 2014-09-01 | 2020-03-11 |
| A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants sublingual buprenorphine tablets, Buprenorphine implant, placebo implants - Opioid Dependence | Phase 3 | Completed | Titan Pharmaceuticals | 177 | 2014-07-01 | 2019-01-11 |
| Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal Lofexidine HCl, Placebo, Open Label Lofexidine HCL - Opioid Dependence, Acute Opioid Withdrawal Syndrome | Phase 3 | Completed | USWM, LLC (dba US WorldMeds) | 603 | 2013-06-01 | 2022-03-22 |
| Dane County Drug Court Study for Addicted Offenders buprenorphine/naloxone - Opioid Dependence | Phase 3 | Completed | University of Wisconsin, Madison | 24 | 2013-03-01 | 2023-06-07 |
| Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway Naltrexone intramuscular suspension, Buprenorphine-naloxone - Opioid Dependence | Phase 3 | Completed | University of Oslo | 166 | 2012-10-01 | 2018-10-11 |
| Distress Tolerance and Buprenorphine Distress Tolerance, Health Education - Opioid Dependence | Phase 3 | Completed | Butler Hospital | 59 | 2012-03-01 | 2015-09-10 |
| Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) Hydromorphone, Injectable, Diacetylmorphine, injectable, Hydromorphone, liquid oral - Opioid Dependence, Heroin Dependence | Phase 3 | Completed | University of British Columbia | 202 | 2011-12-01 | 2016-06-07 |
| Dronabinol Naltrexone Treatment for Opioid Dependence injectable naltrexone and dronabinol, Naltrexone and placebo - Opioid Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 60 | 2010-01-01 | 2018-06-18 |
| Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults Memantine, Placebo - Opioid Dependence | Phase 2 / Phase 3 | Completed | University of Massachusetts, Worcester | 87 | 2009-10-01 | 2015-04-01 |
| Treatment for Opioid Dependent Offenders Methadone, buprenorphine (Suboxone) - Opioid Dependence | Phase 2 / Phase 3 | Completed | University of Wisconsin, Madison | 16 | 2009-06-01 | 2023-06-05 |
| A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence Probuphine (buprenorphine implant), Sublingual Buprenorphine - Opioid Dependence | Phase 3 | Terminated | Titan Pharmaceuticals | 9 | 2008-09-01 | 2018-12-31 |
| Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Vivitrol, memantine - Opioid Dependence, Heroin Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 82 | 2008-06-01 | 2018-07-17 |
Showing 20 of 27. Sign in to see all of them.
Opioid-Related Disorders (27) · Behavior, Addictive (2) · Heroin Dependence (2) · Substance-Related Disorders (2) · Agnosia (1) · Pain, Postoperative (1) · Recurrence (1) · Thoracic Diseases (1)
Chemically-Induced Disorders (27) · Mental Disorders (27) · Narcotic-Related Disorders (27) · Substance-Related Disorders (25) · Behavior (2) · Compulsive Behavior (2) · Impulsive Behavior (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pain (1) · Perceptual Disorders (1)
Buprenorphine (9) · Buprenorphine, Naloxone Drug Combination (8) · Methadone (5) · Heroin (2) · Memantine (2) · lofexidine (2) · vivitrol (2) · Bupivacaine (1) · Case Management (1) · Counseling (1) · Dronabinol (1) · Epinephrine (1) · Fluid Therapy (1) · Hydromorphone (1) · Injections (1)
New York State Psychiatric Institute (4) · Titan Pharmaceuticals (4) · BioDelivery Sciences International (2) · Johns Hopkins University (2) · University of British Columbia (2) · University of Wisconsin, Madison (2) · Bubba Nicholson (1) · Butler Hospital (1) · Indivior Inc. (1) · Massachusetts General Hospital (1) · The University of New South Wales (1) · USWM, LLC (dba US WorldMeds) (1) · University of Massachusetts, Worcester (1) · University of Oslo (1) · University of Pennsylvania (1)
United States (18) · Canada (2) · Australia (1) · Austria (1) · Germany (1) · Iran (1) · Norway (1) · Ukraine (1)
Adam Bisaga, MD (2) · Charles W Gorodetzky, MD, PhD (1) · Christian Haasen, MD (1) · Dieter Naber, MD (1) · Elias Dakwar, MD (1) · Elizabeth Evans, M.D. (1) · Elizabeth Ralevski, Ph.D. (1) · Eric Strain (1) · Eugenia Oveido-Joekes, Ph.D. (1) · Gerardo Gonzalez, M.D. (1) · Harald Ott, MD (1) · Hendree E. Jones, PhD (1) · James G Sullivan, MD (1) · Lars Tanum, MD, PhD (1)
PMID 12873949, PMID 1517644, PMID 15919269, PMID 17341537, PMID 20940383, PMID 21142534, PMID 21715107, PMID 22013534, PMID 22088886, PMID 22227789, PMID 23049275, PMID 23106923, PMID 23106924, PMID 23106925, PMID 23106926, PMID 23106927, PMID 23106928, PMID 23106929, PMID 23106930, PMID 23106931, PMID 23279924, PMID 23523131, PMID 23786504, PMID 23952897, PMID 25619263, PMID 25866297, PMID 25912739, PMID 26308513, PMID 26447431, PMID 26507422, PMID 27042786, PMID 27049826, PMID 27121539, PMID 27434441, PMID 27790554, PMID 28526048, PMID 29049469, PMID 29806872, PMID 30531234, PMID 30566177, PMID 30701613, PMID 30714249, PMID 30792007, PMID 31606589, PMID 32002194, PMID 32737087, PMID 32920647, PMID 34487395, PMID 34736130, PMID 34794061
R01DA015764 (1), R01DA015822 (1), R01DA027124 (1), R01DA027138 (1), R01DA042070 (1), R01DA048761 (1), R21DA021073 (1), U01DA033276 (1)